Raymond Bayonito

Direct full commercial and P&L accountability for Oncology and Bone & Joint business units, coordinating distributed field, marketing, and regulatory teams across the Philippines. Built multi-scenario Excel forecast models and executive PowerPoint decks presented to CEO and Finance VP.

Directed commercial growth strategy and market access initiatives for a specialty therapeutic portfolio, managing external agencies remotely for campaign execution. Led CME programs and omnichannel HCP campaigns to expand specialty-line penetration.

Led a 77-person commercial team against a PHP 12.8 billion annual sales target, achieving 100% YTD performance.

Achieved 108% YTD target for the Established Brands Oncology portfolio (Faslodex, Zoladex, Arimidex, Casodex, Nolvadex) within 3 months of assumption.

Delivered 127% YTD performance; recognized 2019 Franchise of the Year. Pioneered remote detailing (VEEVA Engage), rep-triggered email campaigns, and HCP portal integration during the pandemic. Led the Philippine launch of Kryxana and managed a multi-brand specialty portfolio.

Reached 126% YTD Operating Plan for Rapamune. Pioneered APAC's first Virtual Rep project (Dare to Try), setting the regional digital-engagement standard later adopted across affiliates.

Established Lyrica as the neuropathic-pain market leader across GMA South for 5 consecutive years; coached 9 Medical Representatives; Man of the Year awardee (2011).

Structured 20 scientific CME modules and executed 47 local/international medical conventions across a 10-year commercial career progression.

Completed the Leadership & Management Development Programme at Ateneo de Manila University from 2003 to 2004.

Pursued a Master of Business Administration with a major in Marketing at De La Salle University from 2003 to 2004.

Earned a Bachelor of Arts in Communications from the University of the Philippines Diliman from 1994 to 1997.